Psoriasis and obesity often go hand in hand. These two long-term health issues share similar underlying problems. One key factor is a persistent, low-level inflammation that affects both body fat and skin. This link means that people with psoriasis who are also obese may face a tougher battle. Their skin condition can worsen, and treatments might not work as well. T...
Psoriasis is a tough skin condition. It can be really hard to deal with. It can be mild or severe. It can be a real pain. There are two treatments that are quite popular in Italy. They are risankizumab and secukinumab. Both are known to be effective. They help a lot of people. But which one is better? It depends on what you look at. Let's dive in. First, l...
Psoriasis, a long-term skin disorder causing red, scaly patches, is on the rise globally. However, not many studies have looked into how it's treated and the impact it has on healthcare in places like Germany. Let's dive into some real-world data to understand what's going on. In Germany, a specific insurance database has been tracking treatments and costs related t...
Did you know that age and body mass index (BMI) could play a significant role in how well a psoriasis treatment works? A recent study looked into a medication called deucravacitinib, a type of drug that blocks certain proteins in the body. This study wanted to find out what factors might make some people respond better to this treatment than others. The study includ...
Have you ever wondered how certain cells in our body go haywire and cause conditions like psoriasis? One key player in this puzzle is the mammalian target of rapamycin, or mTOR for short. This pathway is like the body's metabolic traffic cop, controlling how cells grow and divide. Recent research has zoomed in on two specific forms of mTOR: mTORC1 and mTORC2. These ...
Hidradenitis suppurativa (HS) and psoriasis are both long-term inflammatory conditions that share similar immune system pathways. Both diseases involve cytokines like tumor necrosis factor-alpha, interleukin (IL)-17, and IL-23. Currently, treatment choices for HS are limited, with only adalimumab and secukinumab approved for severe cases. Since HS and psoriasis have ...